Obermatt
See Similar Stocks →

Flags

Financial distress

Newron Pharmaceuticals

SWX:NWRN · IT0004147952
PharmaceuticalsSmall

360

15
Profit price92
Owner Earnings Yield1
Dividend Yield1
Price/Sales18
EV / Gross Profit19
Price/Book87
Returns on capital33
EBIT Margin10
Gross Profitability89
Accruals95
Owner Earnings Margin28
Sales growth9
Profit Growth24
Long-Term EPS Growth6
Owner Earnings Growth16
Reinvestment50
Price momentum78
Debt load5
Refinancing34
Debt Payback1
Liquidity43
Analyst ratings100
Opinion Changes50
Price Target Upside100
Market mood63
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Newron Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryItaly
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeSWX
Employees26
Websitenewron.com
ISINIT0004147952
Last UpdateApr 2, 2026
Indices
SPI (Switzerland)
Themes
Pain ManagementPsychiatryNeurologyCentral Nervous SystemNeuroscienceBiopharmaBiotechnologyMedical

Description

Newron Pharmaceuticals S.p.A. (Newron) engages in the research and development of novel pharmaceutical drugs. The company focuses specifically on diseases of the central nervous system (CNS) and aims to address significant unmet medical needs. The co…

Analysis

Middle-of-the-road

Newron Pharmaceuticals S.p.A. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
35
2026

All-time high

91

Mar 2026

All-time low

35

Jun 2026

Average rank

63

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
18
—
—
—
Price/Earnings
79
—
—
—
Price/Book
87
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
69
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Newron Pharmaceuticals with its peers
UCB
BRU:UCB
69
CountryBelgium
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
BeOne Medicines
SHH:688235
91
CountrySwitzerland
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
GH Research
NMQ:GHRS
57
CountryIreland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
AC Immune
NMQ:ACIU
68
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Prothena Corporation
NSQ:PRTA
39
CountryIreland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
MoonLake Immunotherapeutcs
NAQ:MLTX
13
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →